Palms Wrinkle Within Minutes of Water Exposure: When to Ask a Dermatologist

Palms that become swollen, unusually wrinkled, and covered with tiny white or translucent bumps within a few minutes of water contact can fit aquagenic wrinkling of the palms (AWP). Burning, itching, or tightness may accompany the changes, but some people have no discomfort. The reaction usually fades after drying. Repeated episodes during ordinary washing, showering, or swimming are worth discussing with a dermatologist, especially when they are uncomfortable or affect daily activities. DermNet clinical overview.

AWP is associated with cystic fibrosis (CF) and CFTR carrier status, but it also occurs in people without diagnosed CF. Neither a photograph nor the time your hands take to wrinkle establishes either diagnosis. The useful next step is to record naturally occurring episodes, mention relevant symptoms and family history, and ask whether a clinical assessment and sweat chloride testing are appropriate. Your clinician may also consider CFTR genetic testing; a hand reaction cannot replace either test. Yang, Zhou, and Luke review; Healthy-adolescent case.

What aquagenic wrinkling of the palms looks and feels like

AWP is also called aquagenic keratoderma or aquagenic syringeal acrokeratoderma. These names describe the same temporary water-associated palm changes in the sources discussed here. They should not be confused with hereditary papulotranslucent acrokeratoderma, a separate condition with persistent lesions. You do not need to choose the correct technical name before making an appointment: a description of the timing, appearance, and recovery is more useful. Clinical review.

The palms often look normal when dry. Following brief contact with water, they may swell and develop small pale or translucent raised areas along with exaggerated folds. Both palms commonly react, although one-sided cases and occasional involvement of the soles or other sites have been reported. The pattern can look much more dramatic than the ordinary wrinkling noticed after a long bath. DermNet clinical features.

Discomfort varies. Burning, itching, stinging, or tightness can occur, while other episodes are painless. Tell the clinician whether the reaction interferes with work or handling objects instead of assuming that pain is necessary for AWP. In the 2026 controlled study, most children with confirmed CF reported no pain at either the three- or seven-minute observation. Absence of pain therefore does not rule out the CF association, and discomfort alone cannot estimate your individual risk. Controlled immersion study, Table 1.

DermNet describes resolution within about 10–60 minutes after drying, while noting that changes can persist longer. That is a typical range rather than a deadline: the older Katz case series included an episode pattern lasting up to two hours. Record your actual recovery time. Changes that remain between episodes, rather than returning toward the usual dry appearance, are useful details for the dermatologist to assess. DermNet; Katz and colleagues case series.

Normal wrinkling versus AWP: why the minute count matters

The distinction is a pattern of rapid swelling and temporary papules, not a single minute count. The clinical review contrasts AWP appearing within about three minutes with ordinary physiological wrinkling after roughly eleven minutes of immersion. Water conditions and individual responses vary, so a reaction at five minutes does not establish a diagnosis, and a later reaction does not exclude an associated condition. Clinical review.

Ordinary water-induced wrinkling involves nerve-mediated changes in blood vessels. AWP has several proposed mechanisms involving sweat ducts, salt handling, water channels, and the outer skin barrier. The literature does not establish one mechanism that explains every case. In particular, a link to altered CFTR function does not mean that everyone with AWP has a CFTR mutation. Mechanism review; CFTR case discussion.

Salt water is not a reliable discriminator. In the 2005 report, one patient developed changes in tap water but not in a 23% hypertonic saline solution. The same paper describes earlier patients who reacted to both tap water and salt water. That experiment supports an osmotic hypothesis; it does not establish that ocean swimming prevents AWP or that a saline comparison confirms its cause. Simply note the setting of ordinary episodes rather than trying a salt-water test. Katz and colleagues.

The cystic fibrosis link, with real numbers and real limits

CFTR is involved in electrolyte transport, including salt handling in sweat ducts. Altered sweat composition and water movement are possible explanations for the association between CF and AWP, alongside other proposed mechanisms. This biological connection justifies raising the CF question during assessment. It does not turn a visible skin response into a genetic test. Clinical review.

Reported frequencies differ across studies and populations. The 2022 clinical review summarizes AWP in approximately 44–80% of people with CF and about 25% of carriers. These are proportions within studied CF or carrier groups. They are not the probability that a person who notices wrinkled palms has CF. The distinction matters because patients in an established CF cohort differ from people seeking help for a new skin symptom. Yang, Zhou, and Luke.

In a controlled study published in 2026, Alexopoulos and colleagues compared 100 children with CF, 50 adult CFTR carriers who were parents of children with CF, and 100 healthy pediatric controls. The table below reproduces the initial group counts reported in that paper. The children with CF already had a confirmed diagnosis; the study was not a population survey of otherwise healthy people noticing fast-wrinkling hands. Alexopoulos and colleagues, Table 1.

The contrast is strongest early in the reported observations, but the groups overlap. Some carriers and healthy controls had wrinkling at seven minutes, and not every child with CF had early wrinkling. A delayed or absent response therefore cannot settle the carrier question. These results support the authors’ proposal to use clinical observation as a triage clue followed by confirmatory testing, rather than as a home CF screen. Study results and conclusions.

Several limitations restrict how confidently these results can guide an individual decision. The study came from one center, the examiner was not blinded, and the carrier parents were substantially older than the pediatric groups. Environmental factors were not stringently controlled. The paper’s published specificity estimates also do not reconcile with the pooled carrier/control counts shown in its own table. For that reason, this guide uses the reported descriptive counts without presenting a diagnostic-accuracy score or a personal probability of CF. Blinded studies with better matched groups would help clarify the test’s performance. Study methods, tables, and limitations.

When AWP does not mean cystic fibrosis

AWP can be documented without an established CF diagnosis. Bimbi and colleagues described a healthy 12-year-old girl without CF-related symptoms or family history. She developed wrinkling and translucent papules after four minutes of water contact, with recovery within fifteen minutes, and her sweat test was negative. The report does not establish that she had no CFTR variants; a negative sweat test and an absent family history are not equivalent to negative genetic testing. Healthy-adolescent case.

A separate 2018 case discussion by Huang and Cohen in Contemporary Pediatrics described a 16-year-old whose sweat chloride was 26 mmol/L, classified as CF unlikely. The authors cited advice against routine genetic testing for isolated AWP without suggestive symptoms or family history, but also recommended preliminary evaluation for CF. This is a case discussion, not a universal rule for every patient. It supports individualized assessment rather than automatic reassurance or automatic broad genetic testing. Huang and Cohen case discussion.

A normal sweat result does not absolutely exclude every CFTR-related condition. The clinical context still matters, particularly if other symptoms remain unexplained. Tell the clinician about chronic respiratory or digestive symptoms, growth or weight concerns, and relevant family history. Conversely, discovering the association online does not make CF the explanation for your own hands. The evaluation brings the skin finding and the wider history together. CFTR case discussion; Clinical context.

What to record before your appointment: timing, symptoms, medications

Use episodes that already happen during daily activities. There is no need to keep your hands in water until a reaction appears or to repeat a painful episode for a clearer photo. If you happen to notice the onset and recovery, record approximate times. Missing a precise minute count is fine; the clinician can decide whether a supervised observation would add useful information.

If a photograph is available from an ordinary episode, show it alongside a description of what your hands look like when dry. Describe swelling and bumps as well as color: a single image does not reliably convey timing or sensation. Explain whether the problem is simply noticeable or disrupts wet work and other daily tasks. Those details help make the appointment about the decision you need, such as evaluation, symptom relief, or both.

The reviews report medication associations including aspirin, some NSAIDs and COX-2 inhibitors, ACE inhibitors, angiotensin-receptor blockers, and aminoglycoside antibiotics. Much of this evidence comes from case reports, so it does not prove that a drug caused your reaction. A recent start date or dose change is information to share, not a reason to discontinue treatment. Bring the complete list rather than focusing only on a suspected drug. Medication associations; Treatment review.

Keep taking prescribed medicines as directed unless your prescriber changes the plan. Ask whether the timing of your symptoms warrants a medication review and whether another condition could explain them. There is also no reason to begin a strong antiperspirant, acid preparation, oral medicine, or device treatment before the skin changes have been assessed.

What evaluation actually involves: the water test, sweat chloride, genotyping

Diagnosis of AWP is usually clinical: the history, examination, and temporary response to water are considered together. A dermatologist may observe the response under supervision; clinical references describe an observation lasting about seven minutes. This is separate from testing for CF. A biopsy is sometimes used when the presentation is uncertain, but it is not required for every typical case. DermNet diagnosis; Clinical assessment.

Bring up the CF association even if AWP seems isolated. DermNet and the clinical review advise investigating that association, while the case discussion shows how history and examination can guide the extent of testing. Relevant symptoms or a family history increase the importance of assessment, but their absence is not proof that no testing is needed. A suspected medication association should be reviewed alongside the CF question, rather than ending the evaluation.

• Sweat chloride testing measures chloride in collected sweat. It is an objective test interpreted in the context of the person’s symptoms and other findings, rather than a visual assessment of wet palms.

• CFTR genetic testing examines variants in the CFTR gene. The clinician decides whether it is indicated and how to interpret results; a limited panel or a normal sweat result may not resolve every clinically suspicious case.

A useful question is: “What would make further CF testing appropriate in my case, and what happens if the first result is normal but symptoms remain unexplained?” This avoids treating the consultation as a choice between immediate genetic sequencing and no investigation at all. It also leaves room to assess other causes of the hand changes. Testing limitations.

flowchart TD
  A["Notice repeated palm changes during ordinary water contact"] --> B["Record timing, recovery, symptoms, and medications"]
  B --> C["Dermatologist assesses the skin response"]
  C --> D["Review CF association, symptoms, and family history"]
  C --> E["Review possible medication associations with prescriber"]
  D --> F["Clinician decides on sweat chloride and CFTR testing"]
  E --> F
  F --> G["Interpret results in clinical context and plan follow-up"]

Treatments and what the evidence actually supports

Treatment evidence is limited. The clinical reviews describe case reports, small series, and clinical experience rather than controlled comparisons that establish the best option. Improvement in an individual case does not tell us how often an option works, how it compares with another, or whether spontaneous remission contributed. Mild episodes may need no specific treatment, while discomfort or interference with daily activities can justify a discussion of symptom management. Treatment review.

DermNet and the Yang review describe 20% aluminum chloride hexahydrate as a common first treatment clinicians consider. Response is variable: in the Katz series, one patient did not improve and another had moderate improvement with excessive drying. A clinician should choose the formulation and instructions. These reports do not support a universal application schedule or a guarantee of remission. DermNet treatment; Reported treatment outcomes.

The U.S. drug reference published by ASHP on Drugs.com lists different aluminum chloride formulations, including a 20% Drysol solution and a separate 6.25% Xerac AC solution. It describes OTC Certain Dri use for underarm sweating only. These product listings concern sweating; they do not establish that every formulation treats AWP or that an underarm product is suitable for your palms. Ask the dermatologist which exact formulation is being considered, whether it requires a prescription, and what precautions apply. A stronger percentage is not itself evidence of greater benefit. Aluminum chloride monograph.

Formulation also affects safety. The same drug reference describes local irritation, flammability of aluminum chloride solutions, and precautions for people with renal impairment. Mention kidney disease, pregnancy or breastfeeding, and cracked or irritated skin before discussing a topical treatment. This is a reason to review the actual product with the clinician rather than transferring instructions from a different antiperspirant. The AWP reports do not establish a safe, universal regimen for adults and children. Aluminum chloride precautions.

The table summarizes selected topical and noninjection approaches discussed in the clinical reviews. Their evidence for AWP is limited, and the appropriate choice depends on the confirmed skin condition, symptom burden, age, and other health concerns. Treatment evidence review.

The Actas review describes iontophoresis as a possibility when topical treatment has failed, while acknowledging that its mechanism in AWP is unknown and published experience is sparse. It discusses oral oxybutynin and other approaches, but its preference for a particular treatment rests on low-level evidence. That preference should not be read as a proven comparative ranking. Rare surgical reports of thoracic sympathectomy likewise do not make surgery a routine choice for a temporary skin reaction. Carbonell Pradas and Grimalt Santacana review.

When discussing treatment, specify the outcome you want: less pain, fewer disruptive episodes, or relief of coexisting sweating. Ask how improvement will be judged, what adverse effects should prompt contact, and whether stopping treatment is likely to allow symptoms to return. The small reports cannot supply a dependable success percentage. A treatment plan should account for the burden of the condition as well as the limits of the evidence.

If you already have cystic fibrosis: what modulators do to AWP

For people already receiving CF care, small studies suggest that AWP can improve during CFTR-modulator treatment. Jacobi and colleagues followed 16 patients, eight children and eight adults, before and for six months after starting ivacaftor. Thirteen had at least mild AWP at baseline, and the investigators reported improvement with treatment. This small observational study supports the association with CFTR function, while providing limited evidence about long-term outcomes or individual response. Jacobi and colleagues.

Torres-Laboy and colleagues described a 16-year-old with respiratory, digestive, and growth concerns alongside AWP. After diagnosis and treatment with elexacaftor-tezacaftor-ivacaftor, his twenty-four-week examination showed substantially reduced wrinkling with no fissuring or edema. His palm reaction had been painless, contrary to an assumption that AWP must burn. This is one case, not a promise of improvement for everyone. CFTR-modulator decisions belong to CF specialist care, rather than treatment shopping for isolated palm changes. Torres-Laboy and colleagues case report.

Look-alikes: hives, itching, and persistent palm bumps

Water-associated symptoms can describe different conditions. The Yang review lists aquagenic urticaria, aquagenic pruritus, and hereditary papulotranslucent acrokeratoderma as differential diagnoses. Their patterns help explain why the clinician needs more than a photo of creases. The distinctions below are prompts for describing symptoms, rather than a way to diagnose the condition yourself. Differential diagnosis table.

Mention any persistent peeling, cracking, or rash between water episodes as well. Do not force every hand symptom into the AWP pattern. For the appointment, the essential information remains straightforward: what happens during ordinary contact with water, how long it lasts, how it feels, and what else is happening with your health. That record helps the clinician address both the skin symptoms and whether the CF association needs further evaluation.

Sources

• DermNet New Zealand. Aquagenic wrinkling of the palms. Reviewed September 2023. Clinical summary.

• Yang K, Zhou C, Luke J. Aquagenic wrinkling of the palms: review of the literature. Clin Exp Dermatol. 2022;47(11):1910–1915. Clinical review.

• Alexopoulos A, et al. Aquagenic Wrinkling of the Palms as a Screening Indicator for Cystic Fibrosis Beyond Infancy. Cureus. 2026;18(1):e102506. Controlled observational study.

• Jacobi E, et al. Aquagenic wrinkling of the palms in cystic fibrosis patients treated with ivacaftor. J Cyst Fibros. 2022;21(2):e102–e105. Small observational series.

• Katz KA, Yan AC, Turner ML. Aquagenic wrinkling of the palms in patients with cystic fibrosis homozygous for the deltaF508 CFTR mutation. Arch Dermatol. 2005;141(5):621–624. Two-patient case series.

• Bimbi C, et al. Aquagenic wrinkling of the palms in a healthy adolescent. Dermatol Online J. Volume 31, issue 6 (2025); published online January 5, 2026. Single-case report.

• Torres-Laboy PM, Melendez-Montañez JM, De Jesús-Rojas W. Aquagenic Wrinkling of the Palm: A Rare Diagnostic Clue of Cystic Fibrosis and the Response to CFTR-Modulating Therapy. Cureus. 2021;13(4):e14425. Single-case report.

• Carbonell Pradas M, Grimalt Santacana R. [Translated article] Aquagenic Keratoderma: Treatment Update. Actas Dermosifiliogr. 2022;113:T254–T260. Treatment review.

• Huang AH, Cohen B. Girl’s hands shrivel when exposed to water. Contemporary Pediatrics. December 1, 2018. Clinical case discussion.

• Drugs.com / AHFS. Aluminum Chloride (Topical) monograph. Drug reference.